Skip to contentL
Longevity Health Holdings, Inc.
L
XAGELongevity Health Holdings, Inc. Q2 2024 · 10-Q
Revenue$12.32K$12.32K— vs Q2 2023 Net Income-$3.30M-$3.30MN/M vs Q2 2023 EPS Diluted-$4.78-$4.78N/M vs Q2 2023 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Longevity Health Holdings, Inc. · CIK 1842939 · Engraved from SEC EDGAR
-$1,191,487
N/M
Operating Cash Flowderived-$1,138,476N/M Margins · derivedGross margin97.6%
Operating margin-9671.2%
Net margin-26822.5%
ended Jun 30, 2024 · filed Aug 14, 2024 · 45 d after period end